Summary
The effect of neuroleptics on the hypothalamopituitary-adrenal system has been early recognized, but never adequately related to antipsychotic or side effects produced by dopamine antagonists. We are now presenting results showing that the newly characterized dopamine D-1 receptor antagonist, SCH 23390 (0.1 mg/kg i.v.) as well as the mainly dopamine D-2 receptor antagonists, haloperidol (0.1 mg/kg i.v.) and chlorpromazine (1 mg/kg i.v.), produced an increase of cortisol levels (108, 144 and 226% respectively, 20 min after the injection) determined by radioimmunoassay in blood samples collected from superficial veins of the legs of conscious dogs. The 5-HT2 receptor antagonist, cyproheptadine (0.2 mg/kg i.v.), did not modify the cortisol levels. These results suggest that cortisol increase is an effect common to neuroleptic compounds, independently of their relative antagonistic action at dopamine D-1 or D-2 receptors.
This is a preview of subscription content, log in via an institution to check access.
References
Bhattacharya AN, Marks BH (1969) Reserpine-and chlorpromazine-induced changes in hypothalamo-hypophyseal-adrenal system in rats in presence and absence of hypothermia. J Pharmacol Exp Ther 165:108–116
Buckingham JC (1980) Corticotrophin releasing factor. Pharmacol Rev 31:253–275
De Wied D (1967) Chlorpromazine and endocrine function. Pharmacol Rev 19:251–288
Giraud P, Lissitzky J-C, Conte-Devolx B, Gillioz P, Oliver C (1980) Influence of haloperidol on ACTH and B-endorphin secretion in the rat. Eur J Pharmacol 62:215–217
Hicks PE, Schoemaker H, Langer SZ (1984) 5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain. European J Pharmacol 105:339–342
Hyttel J (1983) SCH 23390 — The first selective dopamine D-1 antagonist. Eur J Pharmacol 91:153–154
Hyttel J, Larsen J-J, Christensen AV, Arnt J (1985) Receptor-binding profiles of neuroleptics. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia. Psychopharmacology, Suppl 2. Springer, Berlin Heidelberg New York Tokyo, pp 9–18
Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462–468
Janssen PAJ (1983) 5-HT2 receptor blockade to study serotonin-induced pathology. TIPS 4:198–206
Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatr 137:1518–1522
Seeman P (1985) Brain dopamine receptors in schizophrenia and tardive dyskinesia. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia. Psychopharmacology, Suppl 2. Springer, Berlin Heidelberg New York Tokyo, pp 2–8
Ungerstedt U, Herrera-Marschitz M, Stahle L, Tossman U, Zetterstrom T (1985) Functional classification of different dopamine receptors. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia. Psychopharmacology, Suppl 2. Springer, Berlin Heidelberg New York Tokyo, pp 19–30
Uvnäs-Wallensten K, Goiny M, Oriowo MA, Cekan S (1981) Effect of apomorphine and haloperidol on plasma cortisol levels in conscious dogs. Acta Physiol Scand 112:253–256.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goiny, M., Herrera-Marschitz, M., Uvnäs-Moberg, K. et al. The benzazepine SCH 23390 increases plasma levels of cortisol in the conscious dog. Naunyn-Schmiedeberg's Arch. Pharmacol. 332, 111–112 (1986). https://doi.org/10.1007/BF00633207
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00633207